Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- NEW PRODUCTS
April 13, 2009
- Mochida Aims at ¥84.5 Bil. Sales in FY2011
April 13, 2009
- Actavis ASKA Aims at Sales of ¥10 Bil. by 2015
April 13, 2009
- JKMA Publishes English Terminology for Kampo Medicines
April 13, 2009
- Co-DIO, Ecard Jump to 1st and 2nd Place on GP Market: Rep Track Survey
April 13, 2009
- 22 Companies to Apply for NHI Price Listing for Generics of Cravit
April 13, 2009
- Council to Focus on Differences in Prices of Medical Devices in Japan and Abroad
April 13, 2009
- Pharmacists Hold Key to Promotion of the Use of Generics: Mr Isobe
April 13, 2009
- MEDICAL DEVICE NEWS IN BRIEF
April 13, 2009
- Hansha's Sales Forces May Help Generics Makers Provide Information
April 13, 2009
- JCS (Japanese Circulation Society) 2009
April 13, 2009
- Mylan Seiyaku Kicks Off Cancer-Specialized Team
April 13, 2009
- Lucentis to Become the Mainstay for AMD in Japan as Well
April 13, 2009
- Society of Applied Therapeutics to Be Inaugurated
April 13, 2009
- Optimal Antiviral Therapy Important to Prevent Liver Cancer: Dr Izumi
April 13, 2009
- Daiichi Sankyo to Apply for DU-176b as Japan's First Oral Anti-Xa Agent
April 13, 2009
- Synergistic Effects Can Be Expected with Adoair
April 13, 2009
- Daiichi Sankyo Reshuffles R&D Structures to Quickly Develop Biologics
April 13, 2009
- UFT as Effective as CMF for Postoperative Breast Cancer
April 13, 2009
- Market Growth for Generics Slowed Down in 4th Qtr of 2008
April 6, 2009
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…